Portfolio Holdings Detail for ISIN IE00BYXG2H39
Stock Name / Fund iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer Blackrock
Entity holding fund iShares IV Public Limited Company
Entity Type Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF Ticker BTEC(USD) LSE
ETF Ticker BTEK(GBP) LSE
ETF Ticker 2B70(EUR) F
ETF Ticker 2B70.DE(EUR) CXE
ETF Ticker BTEC.LS(USD) CXE
ETF Ticker BTEK.LS(GBP) CXE
ETF Ticker BTEC.L(GBP) LSE
ETF Ticker BTEK.L(GBP) LSE

Holdings detail for GMAB

Stock Name	Genmab AS
Ticker	GMAB(USD) NASDAQ
TYPE	Common Stock
Country	USA
ISIN	US3723032062
LEI	529900MTJPDPE4MHJ122

Show aggregate GMAB holdings

News associated with GMAB

Genmab A/S Sponsored ADR (NASDAQ:GMAB) Given Consensus Recommendation of “Moderate Buy” by Brokerages: Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) has received an average recommendation of “Moderate Buy” from the eleven research firms that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, six have given a buy rating […] - 2025-08-27 02:38:58
Genmab A/S (NASDAQ:GMAB) Price Target Raised to $36.00: Genmab A/S (NASDAQ:GMAB – Free Report) had its target price lifted by HC Wainwright from $35.00 to $36.00 in a research report sent to investors on Friday morning,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Genmab A/S’s Q1 2026 earnings at $0.34 EPS, Q2 2026 […] - 2025-08-18 03:01:11
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Purchased by Headlands Technologies LLC: Headlands Technologies LLC increased its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 1,525.0% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,560 shares of the company’s stock after purchasing an additional 1,464 shares during the period. […] - 2025-08-14 04:45:19
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Sold by US Bancorp DE: US Bancorp DE lessened its holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 34.6% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 107,553 shares of the company’s stock after selling 56,995 shares during the period. US Bancorp DE’s […] - 2025-08-08 06:22:50
Natixis Advisors LLC Decreases Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB): Natixis Advisors LLC decreased its stake in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 37.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 128,525 shares of the company’s stock after selling 77,244 shares during the quarter. Natixis Advisors LLC’s […] - 2025-08-08 05:24:58
Genmab's Epcoritamab Combo Shows Strong Results In Follicular Lymphoma Trial: (RTTNews) - Genmab A/S (GMAB), Thursday announced positive results from its Phase 3 EPCORE FL-1 trial evaluating subcutaneous epcoritamab in combination with rituximab and lenalidomide for relapsed or refractory follicular lymphoma. - 2025-08-07 12:34:08
XTX Topco Ltd Acquires Shares of 30,929 Genmab A/S Sponsored ADR (NASDAQ:GMAB): XTX Topco Ltd acquired a new position in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) in the first quarter, according to its most recent disclosure with the SEC. The firm acquired 30,929 shares of the company’s stock, valued at approximately $606,000. Other hedge funds and other institutional investors also recently modified their […] - 2025-08-06 05:20:51
Analysts Set Genmab A/S Sponsored ADR (NASDAQ:GMAB) Price Target at $37.80: Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) have been given an average recommendation of “Moderate Buy” by the eleven ratings firms that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, six have given a buy recommendation […] - 2025-08-05 02:55:11
Choreo LLC Grows Position in Genmab A/S Sponsored ADR (NASDAQ:GMAB): Choreo LLC raised its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 19.4% during the first quarter, according to its most recent filing with the SEC. The firm owned 26,040 shares of the company’s stock after purchasing an additional 4,226 shares during the period. Choreo LLC’s holdings in Genmab A/S […] - 2025-07-28 04:38:57
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Sold by Cerity Partners LLC: Cerity Partners LLC decreased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 20.2% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 40,904 shares of the company’s stock after selling 10,360 shares during the period. Cerity Partners LLC’s holdings in Genmab A/S were worth $801,000 at the end of the […] - 2025-07-24 04:34:54
Genmab A/S (NASDAQ:GMAB) Stock Rating Upgraded by Wall Street Zen: Genmab A/S (NASDAQ:GMAB – Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday. A number of other analysts have also commented on GMAB. HC Wainwright reaffirmed a “buy” rating and issued a $37.00 price […] - 2025-07-14 03:54:44
Truist Financial Forecasts Strong Price Appreciation for Genmab A/S (NASDAQ:GMAB) Stock: Genmab A/S (NASDAQ:GMAB – Free Report) had its target price increased by Truist Financial from $45.00 to $46.00 in a research report sent to investors on Tuesday,Benzinga reports. They currently have a buy rating on the stock. Several other analysts also recently weighed in on GMAB. Sanford C. Bernstein downgraded Genmab A/S from a “market […] - 2025-07-11 04:34:48
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Receives Average Rating of “Moderate Buy” from Analysts: Genmab A/S Sponsored ADR (NASDAQ:GMAB – Get Free Report) has received a consensus rating of “Moderate Buy” from the twelve brokerages that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, seven have given a buy recommendation and one has […] - 2025-07-08 03:12:51
Blue Trust Inc. Raises Holdings in Genmab A/S Sponsored ADR (NASDAQ:GMAB): Blue Trust Inc. increased its stake in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 169.9% during the first quarter, according to its most recent filing with the SEC. The institutional investor owned 7,413 shares of the company’s stock after purchasing an additional 4,666 shares during the period. Blue Trust Inc.’s holdings […] - 2025-06-25 04:36:54
Genmab A/S Sponsored ADR (NASDAQ:GMAB) Shares Acquired by QRG Capital Management Inc.: QRG Capital Management Inc. increased its position in Genmab A/S Sponsored ADR (NASDAQ:GMAB – Free Report) by 213.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 74,847 shares of the company’s stock after purchasing an additional 50,990 shares during the quarter. QRG Capital Management […] - 2025-06-20 05:38:52
Genmab A/S (NASDAQ:GMAB) Shares Bought by Squarepoint Ops LLC: Squarepoint Ops LLC lifted its position in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 1,235.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 117,507 shares of the company’s stock after acquiring an additional 108,705 shares during the quarter. Squarepoint Ops […] - 2025-05-28 05:30:52
Dimensional Fund Advisors LP Sells 24,894 Shares of Genmab A/S (NASDAQ:GMAB): Dimensional Fund Advisors LP reduced its holdings in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 35.3% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 45,615 shares of the company’s stock after selling 24,894 shares during the period. Dimensional Fund Advisors LP’s holdings in Genmab A/S were worth $952,000 at the […] - 2025-05-16 04:50:56
Mercer Global Advisors Inc. ADV Trims Stock Position in Genmab A/S (NASDAQ:GMAB): Mercer Global Advisors Inc. ADV reduced its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 18.7% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 20,843 shares of the company’s stock after selling 4,804 shares during the quarter. Mercer […] - 2025-05-14 05:34:56
CANADA LIFE ASSURANCE Co Sells 1,143 Shares of Genmab A/S (NASDAQ:GMAB): CANADA LIFE ASSURANCE Co lowered its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 42.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,567 shares of the company’s stock after selling 1,143 shares during the quarter. CANADA LIFE ASSURANCE […] - 2025-05-01 05:50:46
Bank of Montreal Can Has $670,000 Stock Holdings in Genmab A/S (NASDAQ:GMAB): Bank of Montreal Can decreased its stake in Genmab A/S (NASDAQ:GMAB – Free Report) by 57.7% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 32,109 shares of the company’s stock after selling 43,710 shares during the quarter. Bank of Montreal Can’s holdings in Genmab […] - 2025-04-21 04:38:47
Envestnet Asset Management Inc. Has $15.11 Million Holdings in Genmab A/S (NASDAQ:GMAB): Envestnet Asset Management Inc. decreased its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 30.6% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 723,781 shares of the company’s stock after selling 319,779 shares during the quarter. Envestnet Asset Management Inc. owned […] - 2025-04-16 05:05:01
Genmab A/S (NASDAQ:GMAB) Shares Sold by Orion Portfolio Solutions LLC: Orion Portfolio Solutions LLC lessened its stake in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 18.4% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 17,376 shares of the company’s stock after selling 3,919 shares during the quarter. Orion Portfolio Solutions LLC’s […] - 2025-04-09 05:02:51
Genmab A/S (NASDAQ:GMAB) Stock Rating Lowered by Sanford C. Bernstein: Genmab A/S (NASDAQ:GMAB – Get Free Report) was downgraded by analysts at Sanford C. Bernstein from a “market perform” rating to an “underperform” rating in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. GMAB has been the subject of several other reports. Truist Financial reduced their price objective on Genmab A/S […] - 2025-04-03 04:41:01
Genmab A/S (NASDAQ:GMAB) Receives $41.33 Consensus PT from Brokerages: Shares of Genmab A/S (NASDAQ:GMAB – Get Free Report) have been given an average rating of “Moderate Buy” by the thirteen analysts that are currently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation, eight have assigned a buy recommendation and […] - 2025-04-02 02:51:03
Genmab A/S (NASDAQ:GMAB) Holdings Decreased by Envestnet Portfolio Solutions Inc.: Envestnet Portfolio Solutions Inc. reduced its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 20,077 shares of the company’s stock after selling 8,330 shares during the period. Envestnet Portfolio […] - 2025-03-27 06:43:00
How The Pieces Add Up: FBT Targets $219: Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-03-17 09:50:34
Genmab A/S (NASDAQ:GMAB) Shares Sold by Assetmark Inc.: Assetmark Inc. lowered its position in Genmab A/S (NASDAQ:GMAB – Free Report) by 78.1% during the fourth quarter, Holdings Channel.com reports. The fund owned 18,109 shares of the company’s stock after selling 64,520 shares during the quarter. Assetmark Inc.’s holdings in Genmab A/S were worth $378,000 at the end of the most recent quarter. Other […] - 2025-03-13 06:37:04
Genmab A/S (NASDAQ:GMAB) Raised to Outperform at William Blair: Genmab A/S (NASDAQ:GMAB – Get Free Report) was upgraded by William Blair from a “market perform” rating to an “outperform” rating in a note issued to investors on Tuesday, Marketbeat reports. William Blair also issued estimates for Genmab A/S’s FY2028 earnings at $4.06 EPS. A number of other brokerages have also weighed in on GMAB. […] - 2025-03-13 04:18:47
Genmab A/S (NASDAQ:GMAB) Stock Holdings Trimmed by QRG Capital Management Inc.: QRG Capital Management Inc. lowered its holdings in shares of Genmab A/S (NASDAQ:GMAB – Free Report) by 19.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 23,857 shares of the company’s stock after selling 5,579 shares during the period. QRG Capital […] - 2025-03-06 09:19:40
Blue Trust Inc. Grows Stock Position in Genmab A/S (NASDAQ:GMAB): Blue Trust Inc. grew its holdings in Genmab A/S (NASDAQ:GMAB – Free Report) by 33.4% during the fourth quarter, HoldingsChannel reports. The fund owned 5,757 shares of the company’s stock after purchasing an additional 1,442 shares during the period. Blue Trust Inc.’s holdings in Genmab A/S were worth $120,000 as of its most recent SEC […] - 2025-02-07 07:38:11

iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) GMAB holdings

Date	Number of GMAB Shares Held	Base Market Value of GMAB Shares	Local Market Value of GMAB Shares	Change in GMAB Shares Held	Change in GMAB Base Value	Current Price per GMAB Share Held	Previous Price per GMAB Share Held
2025-11-11 (Tuesday)	26,909	USD 815,612	USD 815,612	0	USD 33,636	USD 30.31	USD 29.06
2025-11-10 (Monday)	26,909	USD 781,976	USD 781,976	69	USD 12,742	USD 29.06	USD 28.66
2025-11-07 (Friday)	26,840	USD 769,234	USD 769,234	0	USD -4,832	USD 28.66	USD 28.84
2025-11-06 (Thursday)	26,840	USD 774,066	USD 774,066	69	USD -7,379	USD 28.84	USD 29.19
2025-11-05 (Wednesday)	26,771	USD 781,445	USD 781,445	0	USD 11,511	USD 29.19	USD 28.76
2025-11-04 (Tuesday)	26,771	USD 769,934	USD 769,934	69	USD 3,320	USD 28.76	USD 28.71
2025-11-03 (Monday)	26,702	USD 766,614	USD 766,614	0	USD 2,670	USD 28.71	USD 28.61
2025-10-31 (Friday)	26,702	USD 763,944	USD 763,944	0	USD -1,602	USD 28.61	USD 28.67
2025-10-30 (Thursday)	26,702	USD 765,546	USD 765,546	345	USD 2,511	USD 28.67	USD 28.95
2025-10-29 (Wednesday)	26,357	USD 763,035	USD 763,035	138	USD -724	USD 28.95	USD 29.13
2025-10-28 (Tuesday)	26,219	USD 763,759	USD 763,759	0	USD 2,621	USD 29.13	USD 29.03
2025-10-27 (Monday)	26,219	USD 761,138	USD 761,138	0	USD -22,548	USD 29.03	USD 29.89

Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of GMAB by Blackrock for IE00BYXG2H39

Show aggregate share trades of GMAB

Date Action Quantity Market High Market Low Likely Trade Price Likely Trade Value (Profit/Loss) Average Price previous trades
2025-11-10 BUY 69 29.580 28.885 28.955 USD 1,998 22.47
2025-11-06 BUY 69 29.350 28.150 28.270 USD 1,951 22.41
2025-11-04 BUY 69 29.390 28.510 28.598 USD 1,973 22.34
2025-10-30 BUY 345 28.865 28.320 28.374 USD 9,789 22.24
2025-10-29 BUY 138 28.950 29.300 29.265 USD 4,039 22.21
2025-10-22 SELL -276 29.920 30.240 30.208 USD -8,337 22.01 Loss of -2,263 on sale
2025-10-20 BUY 138 30.540 31.500 31.404 USD 4,334 21.92
2025-10-17 BUY 345 33.170 33.185 33.184 USD 11,448 21.86
2025-10-15 BUY 552 32.720 32.930 32.909 USD 18,166 21.80
2025-10-03 BUY 483 33.560 33.610 33.605 USD 16,231 21.67
2025-10-02 BUY 69 32.120 32.240 32.228 USD 2,224 21.61
2025-09-30 BUY 138 30.670 30.845 30.827 USD 4,254 21.50
2025-09-26 BUY 138 29.070 29.115 29.110 USD 4,017 21.41
2025-09-25 BUY 138 28.840 29.360 29.308 USD 4,045 21.37
2025-09-24 SELL -1,586 29.450 29.515 29.508 USD -46,800 21.32 Loss of -12,983 on sale
2025-09-18 BUY 74 28.040 28.105 28.098 USD 2,079 21.28
2025-09-17 BUY 222 28.080 28.275 28.255 USD 6,273 21.24
2025-08-20 SELL -296 24.060 24.390 24.357 USD -7,210 21.14 Loss of -951 on sale
2025-07-30 BUY 296 22.270 22.560 22.531 USD 6,669 21.09
2025-07-17 SELL -148 22.010 22.165 22.150 USD -3,278 21.00 Loss of -170 on sale
2025-07-11 SELL -592 21.400 21.700 21.670 USD -12,829 20.99 Loss of -402 on sale
2025-07-07 BUY 222 20.520 20.560 20.556 USD 4,563 20.98
2025-07-02 BUY 4,070 20.440 20.585 20.570 USD 83,722 20.99
2025-06-20 BUY 1,202 21.160 21.450 21.421 USD 25,748 20.99
2025-06-11 BUY 140 22.630 22.889 22.863 USD 3,201 20.92
2025-06-10 BUY 140 22.840 22.925 22.916 USD 3,208 20.90
2025-06-04 SELL -70 21.780 22.150 22.113 USD -1,548 20.87 Loss of -87 on sale
2025-04-23 BUY 70 20.130 20.390 20.364 USD 1,425 20.96
2025-04-10 SELL -560 18.010 18.700 18.631 USD -10,433 21.11 Profit of 1,387 on sale
2025-04-08 SELL -70 17.980 18.920 18.826 USD -1,318 21.17 Profit of 164 on sale
2025-04-07 SELL -70 18.190 18.680 18.631 USD -1,304 21.20 Profit of 180 on sale
2025-04-04 SELL -350 18.390 18.885 18.836 USD -6,592 21.24 Profit of 841 on sale
2025-04-01 BUY 288 18.660 19.100 19.056 USD 5,488 21.30
2025-03-31 SELL -213 19.580 19.660 19.652 USD -4,186 21.32 Profit of 355 on sale
2025-03-21 BUY 1,177 19.760 19.940 19.922 USD 23,448 21.45
2025-03-14 SELL -1,072 20.510 21.070 21.014 USD -22,527 21.53 Profit of 554 on sale
2025-03-07 SELL -134 24.140 24.325 24.307 USD -3,257 21.55 Loss of -370 on sale
2025-03-04 SELL -67 23.330 23.455 23.442 USD -1,571 21.44 Loss of -134 on sale
2025-02-25 BUY 134 22.960 23.210 23.185 USD 3,107 21.33
2025-02-19 SELL -67 21.970 22.060 22.051 USD -1,477 21.26 Loss of -53 on sale
2025-02-13 BUY 201 20.920 20.980 20.974 USD 4,216 21.25
2025-02-12 BUY 67 19.690 19.710 19.708 USD 1,320 21.28
2025-02-11 BUY 268 18.890 19.130 19.106 USD 5,120 21.33
2024-12-30 SELL -2,062 20.770 20.880 20.869 USD -43,032 21.98 Profit of 2,285 on sale
2024-11-18 SELL -1,080 20.670 20.845 20.827 USD -22,494 22.78 Profit of 2,107 on sale
2024-11-08 SELL -72 23.080 23.180 23.170 USD -1,668 22.78 Loss of -28 on sale
2024-10-21 SELL -72 22.780 22.800 22.798 USD -1,641 0.00 Loss of -1,641 on sale
Market high and low price is on the date.

Date	Action	Quantity	Market High	Market Low	Likely Trade Price	Likely Trade Value (Profit/Loss)	Average Price previous trades
2025-11-10	BUY	69	29.580	28.885	28.955	USD 1,998	22.47
2025-11-06	BUY	69	29.350	28.150	28.270	USD 1,951	22.41
2025-11-04	BUY	69	29.390	28.510	28.598	USD 1,973	22.34
2025-10-30	BUY	345	28.865	28.320	28.374	USD 9,789	22.24
2025-10-29	BUY	138	28.950	29.300	29.265	USD 4,039	22.21
2025-10-22	SELL	-276	29.920	30.240	30.208	USD -8,337	22.01 Loss of -2,263 on sale
2025-10-20	BUY	138	30.540	31.500	31.404	USD 4,334	21.92
2025-10-17	BUY	345	33.170	33.185	33.184	USD 11,448	21.86
2025-10-15	BUY	552	32.720	32.930	32.909	USD 18,166	21.80
2025-10-03	BUY	483	33.560	33.610	33.605	USD 16,231	21.67
2025-10-02	BUY	69	32.120	32.240	32.228	USD 2,224	21.61
2025-09-30	BUY	138	30.670	30.845	30.827	USD 4,254	21.50
2025-09-26	BUY	138	29.070	29.115	29.110	USD 4,017	21.41
2025-09-25	BUY	138	28.840	29.360	29.308	USD 4,045	21.37
2025-09-24	SELL	-1,586	29.450	29.515	29.508	USD -46,800	21.32 Loss of -12,983 on sale
2025-09-18	BUY	74	28.040	28.105	28.098	USD 2,079	21.28
2025-09-17	BUY	222	28.080	28.275	28.255	USD 6,273	21.24
2025-08-20	SELL	-296	24.060	24.390	24.357	USD -7,210	21.14 Loss of -951 on sale
2025-07-30	BUY	296	22.270	22.560	22.531	USD 6,669	21.09
2025-07-17	SELL	-148	22.010	22.165	22.150	USD -3,278	21.00 Loss of -170 on sale
2025-07-11	SELL	-592	21.400	21.700	21.670	USD -12,829	20.99 Loss of -402 on sale
2025-07-07	BUY	222	20.520	20.560	20.556	USD 4,563	20.98
2025-07-02	BUY	4,070	20.440	20.585	20.570	USD 83,722	20.99
2025-06-20	BUY	1,202	21.160	21.450	21.421	USD 25,748	20.99
2025-06-11	BUY	140	22.630	22.889	22.863	USD 3,201	20.92
2025-06-10	BUY	140	22.840	22.925	22.916	USD 3,208	20.90
2025-06-04	SELL	-70	21.780	22.150	22.113	USD -1,548	20.87 Loss of -87 on sale
2025-04-23	BUY	70	20.130	20.390	20.364	USD 1,425	20.96
2025-04-10	SELL	-560	18.010	18.700	18.631	USD -10,433	21.11 Profit of 1,387 on sale
2025-04-08	SELL	-70	17.980	18.920	18.826	USD -1,318	21.17 Profit of 164 on sale
2025-04-07	SELL	-70	18.190	18.680	18.631	USD -1,304	21.20 Profit of 180 on sale
2025-04-04	SELL	-350	18.390	18.885	18.836	USD -6,592	21.24 Profit of 841 on sale
2025-04-01	BUY	288	18.660	19.100	19.056	USD 5,488	21.30
2025-03-31	SELL	-213	19.580	19.660	19.652	USD -4,186	21.32 Profit of 355 on sale
2025-03-21	BUY	1,177	19.760	19.940	19.922	USD 23,448	21.45
2025-03-14	SELL	-1,072	20.510	21.070	21.014	USD -22,527	21.53 Profit of 554 on sale
2025-03-07	SELL	-134	24.140	24.325	24.307	USD -3,257	21.55 Loss of -370 on sale
2025-03-04	SELL	-67	23.330	23.455	23.442	USD -1,571	21.44 Loss of -134 on sale
2025-02-25	BUY	134	22.960	23.210	23.185	USD 3,107	21.33
2025-02-19	SELL	-67	21.970	22.060	22.051	USD -1,477	21.26 Loss of -53 on sale
2025-02-13	BUY	201	20.920	20.980	20.974	USD 4,216	21.25
2025-02-12	BUY	67	19.690	19.710	19.708	USD 1,320	21.28
2025-02-11	BUY	268	18.890	19.130	19.106	USD 5,120	21.33
2024-12-30	SELL	-2,062	20.770	20.880	20.869	USD -43,032	21.98 Profit of 2,285 on sale
2024-11-18	SELL	-1,080	20.670	20.845	20.827	USD -22,494	22.78 Profit of 2,107 on sale
2024-11-08	SELL	-72	23.080	23.180	23.170	USD -1,668	22.78 Loss of -28 on sale
2024-10-21	SELL	-72	22.780	22.800	22.798	USD -1,641	0.00 Loss of -1,641 on sale

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of GMAB

Date	Shorted Volume	Short Exempt Volume	Total Shares Traded	% Shorted
2025-09-19	189,720	26	720,302	26.3%
2025-09-18	201,398	0	388,501	51.8%
2025-09-17	229,943	0	706,434	32.5%
2025-09-16	178,547	0	354,389	50.4%
2025-09-15	253,030	0	534,521	47.3%
2025-09-12	318,011	0	734,436	43.3%
2025-09-11	297,222	3,503	528,935	56.2%
2025-09-10	248,805	0	425,629	58.5%
2025-09-09	316,681	0	606,383	52.2%
2025-09-08	207,670	0	352,087	59.0%
2025-09-05	649,585	0	1,531,707	42.4%
2025-09-04	295,750	0	506,105	58.4%
2025-09-03	512,692	900	931,004	55.1%
2025-09-02	367,775	1,240	665,074	55.3%
2025-08-29	107,887	0	203,372	53.0%
2025-08-28	235,450	0	509,768	46.2%
2025-08-27	145,179	0	384,156	37.8%
2025-08-26	151,413	150	287,197	52.7%
2025-08-25	281,511	0	413,469	68.1%
2025-08-22	195,683	23	431,662	45.3%
2025-08-21	296,630	0	657,063	45.1%
2025-08-20	150,629	0	298,807	50.4%
2025-08-19	150,263	0	313,970	47.9%
2025-08-18	155,319	0	301,940	51.4%
2025-08-15	249,544	0	575,198	43.4%
2025-08-14	152,693	0	295,418	51.7%
2025-08-13	160,723	65	312,801	51.4%
2025-08-12	205,122	24	371,853	55.2%
2025-08-11	97,088	0	259,951	37.3%
2025-08-08	163,695	0	526,965	31.1%
2025-08-07	302,376	0	1,002,252	30.2%
2025-08-06	236,780	0	510,723	46.4%
2025-08-05	121,067	0	272,083	44.5%
2025-08-04	136,318	0	380,846	35.8%
2025-08-01	166,281	0	406,242	40.9%
2025-07-31	134,620	0	335,843	40.1%
2025-07-30	129,599	0	294,889	43.9%
2025-07-29	124,521	100	269,984	46.1%
2025-07-28	88,368	0	183,921	48.0%
2025-07-25	87,840	0	283,942	30.9%
2025-07-24	111,063	3	569,344	19.5%
2025-07-23	147,573	0	736,106	20.0%
2025-07-22	130,163	0	264,673	49.2%
2025-07-21	129,894	0	245,476	52.9%
2025-07-18	126,767	166	239,762	52.9%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.

Stock Name / Fund	iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)
Issuer	Blackrock
Entity holding fund	iShares IV Public Limited Company
Entity Type	Umbrella investment company with variable capital and having segregated liability between its funds
Entity LEI	549300ZP07LMR36K1T02
ETF Ticker	BTEC(USD) LSE
ETF Ticker	BTEK(GBP) LSE
ETF Ticker	2B70(EUR) F
ETF Ticker	2B70.DE(EUR) CXE
ETF Ticker	BTEC.LS(USD) CXE
ETF Ticker	BTEK.LS(GBP) CXE
ETF Ticker	BTEC.L(GBP) LSE
ETF Ticker	BTEK.L(GBP) LSE